FEATURED SEARCH: migraine
For patients with migraine, it’s O.K. to inhale – MAP0004, an orally inhaled dihydroergotamine(Drug information on dihydroergotamine) (DHE). Among 902 patients in an FDA phase 3 trial, those with migraines received MAP0004 in time frames ranging from immediately to more than eight hours after the onset of a headache. MAP0004 was significantly more effective than a placebo at all treatment points, the researchers found.
RESULT: MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments
Mayo Clinic Proceedings | Oct 1, 2011 (Free abstract. Full text $11)
DHE is more effective than other agents for difficult-to-treat migraine, says this recent review. The medication has a more benign adverse event profile than many people seem to think, say the authors from Cleveland Clinic Florida.
RESULT: Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
Expert Opinion on Pharmacotherapy (PubMed) | Dec 1, 2010 (Free abstract. Full text $86)
Journal of the Association of Physicians of India | Aug 1, 2011 (Free full text)